Asston Pharmaceuticals Limited has announced that its board of directors approved a car loan facility from HDFC Bank Limited during a meeting held on January 5, 2026. The decision was made in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Meeting Details

The board meeting was conducted at the company's registered office from 3:00 PM to 4:30 PM on January 5, 2026. Company Secretary and Compliance Officer Rishi Upadhaya signed the disclosure document, ensuring proper regulatory compliance for the listed pharmaceutical company.

Loan Facility Specifications

The approved car loan facility includes specific terms and security arrangements as outlined by the board:

Security and Terms Structure

The loan facility will be secured against the moveable assets to be purchased with the loan proceeds, specifically the vehicles themselves. This self-securing arrangement provides HDFC Bank with direct collateral tied to the loan's intended use. The specific tenure and interest rate details will be determined through the formal loan agreement to be executed between Asston Pharmaceuticals Limited and HDFC Bank Limited.

Regulatory Compliance

The company has fulfilled its disclosure obligations under SEBI regulations by promptly informing BSE Limited about this material development. The announcement was made to the BSE Listing and Compliance Department, referencing the company's ISIN code INE0SJX01015 and BSE code 544445. This disclosure ensures transparency for shareholders and market participants regarding the company's financing decisions and capital allocation strategies.

Asston Pharmaceuticals Limited, a prominent player in the pharmaceutical sector, has announced a series of strategic moves aimed at strengthening its corporate structure and facilitating growth. The company's board of directors approved several key appointments and funding arrangements in a meeting held on October 16, 2025.

Leadership Appointments

The board has made significant additions to its leadership team:

1. Mr. Yogesh Supekar has been appointed as an Additional Non-Executive Non-Independent Director. With an MBA in Finance and 24 years of experience across banking, media, and public relations, Mr. Supekar brings a wealth of financial acumen to the board.

2. Mr. Rishi Upadhaya joins as the new Company Secretary and Compliance Officer. Mr. Upadhaya, aged 28, is a qualified Company Secretary with a strong academic background in commerce and is currently pursuing an LLB.

3. M/s Yash A. Jain & Associates has been appointed as the internal auditor for the fiscal year 2025-2026. Led by CA Yash Jain, the firm brings over 5 years of expertise in corporate advisory, audit, assurance, and tax services.

Funding Initiatives

Asston Pharmaceuticals has also secured significant funding to support its growth plans:

1. The board has approved an interest-free unsecured loan of up to Rs 3.00 crore from the company's directors. This loan can be introduced either as a lump sum or in tranches.

2. A secured loan facility of up to Rs 2.70 crore from HDFC Bank has been approved for the purchase of commercial space. The loan will be secured against the property to be acquired.

Financial Implications

These financial moves indicate Asston Pharmaceuticals' commitment to expansion and operational enhancement. The interest-free loan from directors showcases their confidence in the company's future prospects.

Compliance and Governance

All appointments have been made in compliance with regulatory requirements. Notably, Mr. Yogesh Supekar is not debarred from holding a directorship by any SEBI or other regulatory order. The company has affirmed that none of the new appointees are related to existing directors, ensuring independence in decision-making.

These strategic decisions by Asston Pharmaceuticals suggest a focus on strengthening corporate governance, enhancing financial capabilities, and laying the groundwork for future growth in the pharmaceutical sector.